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LETTERS TO THE EDITOREvaluation of Response in
Hepatitic Variant of Acute
Liver Graft-versus-Host
Disease
Acute graft-versus-host disease (aGVHD) causes
serious morbidity and mortality after allogeneic hema-
topoietic stem cell transplantation. Recently, Martin
et al. [1] defined important endpoints for clinical trials
testing treatment of aGVHD. Criteria for very good
partial response (VGPR) of aGVHD were described
for skin, liver, and gut. Correct and objective evaluation
of treatment response is very important, and the new
category of VGPR can be useful for several reasons
discussed by Martin et al. [1] in their article. Persisting
low-level hyperbilirubinemia is allowed, which might
be related to antecedent regimen-relatedhepatotoxicity,
or administrationofhepatotoxic agents, orother factors.
Total serum bilirubin concentration was recom-
mended as the single parameter for evaluation of liver
aGVHD treatment response. Elevation of bilirubin
had been established as a standard parameter for classic
liver aGVHDmany years ago [2] and is used in the cur-
rent GVHD classification system [3]. However, the
usefulness of liver enzyme measurement for the diag-
nosis of liver GVHD has been emphasized by several
authors [4,5]. Serum levels of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) are fre-
quently elevated, especially during the early stages of
GVHD [4]. Hepatitic variant of liver GVHD with
elevations of ALT and AST and without the elevation
of bilirubin [6,7] or with elevations of ALT, AST, and
alkaline phosphatase (ALP) has been described previ-
ously [5]. Hepatitic variant of liver GVHD is not
uncommon, and its incidence may be as high as
36%-50% of all liver GVHD cases according to
some authors [5,6].
Therefore, when defining liver aGVHD response
criteria, it is very important to also target the hepatitic
variant. However, it is not specifically mentioned in
the current recommendation [1].
In our previous articles [7,8] that are not cited in
the current recommendation [1], we have defined
treatment responses of liver hepatitic aGVHD for
the first time as follows: partial response—decrease
in level of aminotransferases to\50% of initial levels
and .2 upper limit of normal range, complete
response—decrease in the level of transaminases to
\2 upper limit of normal range. These definitionshave been successfully used in the clinical setting
[7,8]. Complete response is usually defined as a resolu-
tion of all signs and symptoms of aGVHD but the cri-
teria for this response category may be too stringent
[1]. When defining complete response, we deliberately
selected transaminase values of up to 2 times the upper
limit of norm, because complete normalization is rare
after allogeneic transplantation for reasons discussed
above. Indeed, our definition of complete response is
similar to the VGPR definition according to the pro-
posed new terminology.
In conclusion, we believe that the VGPR category
is very practical from the clinical point of view as it
mirrors the complex nature of liver damage after
hematopoietic stem cell transplantation. On the other
hand, however, response criteria for liver GVHD
should include specific definition of the hepatitic
variant. We suggest that our definition proven in the
clinical practice could be used.REFERENCES
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